Journal list menu
Export Citations
Download PDFs
ISSUE INFORMATION
INTRODUCTION
January 2023 at a glance: focus on acute heart failure and medical therapy
- Pages: 1-3
- First Published: 30 January 2023
PATHOPHYSIOLOGY
Research article
Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers
- Pages: 4-13
- First Published: 11 October 2022
Invited editorial
The attack of the clones to the cardiovascular system
- Pages: 14-16
- First Published: 05 December 2022
Research article
Exercise-induced changes in pulmonary artery wedge pressure in adults post-Fontan versus heart failure with preserved ejection fraction and non-cardiac dyspnoea
- Pages: 17-25
- First Published: 04 October 2022

Serial changes in pulmonary artery wedge pressure (PAWP) and PAWP to Qs slopes in adult Fontan patients, heart failure with preserved ejection fraction (HFpEF) and non-cardiac dyspnoea (NCD) (p-values in red correspond to differences between Fontan and HFpEF patients while those in gray correspond to differences between Fontan and NCD for each phase).
Invited editorial
Understanding mechanisms of Fontan failure: exercise haemodynamics to unmask diastolic dysfunction, again!
- Pages: 26-29
- First Published: 15 December 2022
ACUTE HEART FAILURE
Viewpoint
Targeting the ‘vulnerable’ period – first 3–6 months after an acute heart failure admission – the light gets brighter
- Pages: 30-34
- First Published: 15 December 2022
Research articles
Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
- Pages: 35-42
- First Published: 16 September 2022
Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF
- Pages: 43-51
- First Published: 04 October 2022
Invited editorial
Time to diuretics in acute heart failure: the tortoise or the hare?
- Pages: 52-53
- First Published: 09 November 2022
Short report
Health-related quality of life in acute heart failure: association between patient-reported symptoms and markers of congestion
- Pages: 54-60
- First Published: 25 September 2022

Association between patient-reported symptoms and markers of congestion. AHF, acute heart failure; IVC, inferior vena cava; JVD, jugular venous distention; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; NRS, numeric rating scale; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TR, tricuspid regurgitation.
Invited editorial
Identification and quantification of congestion in heart failure: a work in progress
- Pages: 61-62
- First Published: 04 December 2022
ATRIAL FIBRILLATION
Research article
Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry
- Pages: 63-73
- First Published: 07 November 2022

Atrial fibrillation in heart failure with mildly reduced and preserved ejection fraction. AF, atrial fibrillation; CI, confidence interval; GWTG-HF, Get With The Guidelines-Heart Failure; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio.
Invited editorial
The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: a call to action for detecting atrial fibrillation and improving outcome
- Pages: 74-76
- First Published: 15 December 2022
Research article
Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction
- Pages: 77-86
- First Published: 11 October 2022

In intention-to-treat analyses, early routine catheter ablation (CA) resulted in similar long-term outcomes to a delayed selective CA strategy in patients with persistent or long-standing persistent atrial fibrillation (AF) and symptomatic heart failure with reduced ejection fraction (HFrEF) enrolled in the ARC-HF and CAMTAF clinical trials. Medical therapy refers to pharmacological rate control. Kaplan–Meier survival curves shown for all-cause death (left) and a composite outcome of all-cause death or cardiovascular (CV) hospitalization (right). CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NYHA, New York Heart Association.
MEDICAL THERAPY
Research article
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial
- Pages: 87-94
- First Published: 01 October 2022
Invited editorial
Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
- Pages: 95-97
- First Published: 29 November 2022
Research articles
The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure
- Pages: 98-107
- First Published: 20 November 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
- Pages: 108-113
- First Published: 27 October 2022
Invited editorial
Improve heart function to improve heart failure outcomes: the disease-modifying effects of spironolactone
- Pages: 114-116
- First Published: 15 December 2022
Research article
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced
- Pages: 117-127
- First Published: 02 November 2022

EMPEROR-Reduced: effect of empagliflozin on heart failure outcomes, kidney function decline and weight according to body mass index categories. BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure; HR, hazard ratio; Wk, week.
Invited editorial
Weighing in on weight loss in heart failure with reduced ejection fraction
- Pages: 128-130
- First Published: 15 December 2022
RESEARCH LETTER
Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor treatment
- Pages: 131-132
- First Published: 15 December 2022
LETTERS TO THE EDITOR
Letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’
- Page: 133
- First Published: 06 September 2022
Reply to the letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’
- Pages: 133-134
- First Published: 11 October 2022